Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H18N2O6 |
Molecular Weight | 346.3353 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(C(c2ccccc2N(=O)=O)C(=C(C)N1)C(=O)OC)C(=O)OC
InChI
InChIKey=HYIMSNHJOBLJNT-UHFFFAOYSA-N
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
Molecular Formula | C17H18N2O6 |
Molecular Weight | 346.3353 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB01115Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020198s023lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB01115
Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020198s023lbl.pdf
Nifedipine has been formulated as both a long- and short-acting 1,4-dihydropyridine calcium channel blocker. Nifedipine is sold under the brand names Adalat and Procardia among others. Nifedipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. The vasodilatory effects of nifedipine result in an overall decrease in blood pressure. Nifedipine is used for the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3368504
Curator's Comment:: nifedipine can easily cross the blood-brain barrier in the rat
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: http://www.genome.jp/dbget-bin/www_bget?D00437 |
2.0 µM [IC50] | ||
Target ID: CHEMBL1940 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2435904 |
1.0 nM [Ki] | ||
Target ID: CHEMBL1075226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25893973 |
37.5 µM [IC50] | ||
Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24399740 |
7.8 µM [IC50] | ||
Target ID: Cholangiocarcinoma, Mz-ChA-1, human Sources: https://www.ncbi.nlm.nih.gov/pubmed/21179572 |
15.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROCARDIA Approved UseI. Vasospastic Angina
PROCARDIA (nifedipine) is indicated for the management of vasospastic angina confirmed by
any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment
elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically
demonstrated coronary artery spasm. In those patients who have had angiography, the presence of
significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina,
provided that the above criteria are satisfied. PROCARDIA may also be used where the clinical
presentation suggests a possible vasospastic component but where vasospasm has not been
confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to
nitrates and/or adequate doses of beta blockers.
II. Chronic Stable Angina
(Classical Effort-Associated Angina)
PROCARDIA is indicated for the management of chronic stable angina (effort-associated
angina) without evidence of vasospasm in patients who remain symptomatic despite adequate
doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. Launch Date3.78518405E11 |
|||
Primary | PROCARDIA Approved UseI. Vasospastic Angina
PROCARDIA (nifedipine) is indicated for the management of vasospastic angina confirmed by
any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment
elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically
demonstrated coronary artery spasm. In those patients who have had angiography, the presence of
significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina,
provided that the above criteria are satisfied. PROCARDIA may also be used where the clinical
presentation suggests a possible vasospastic component but where vasospasm has not been
confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to
nitrates and/or adequate doses of beta blockers.
II. Chronic Stable Angina
(Classical Effort-Associated Angina)
PROCARDIA is indicated for the management of chronic stable angina (effort-associated
angina) without evidence of vasospasm in patients who remain symptomatic despite adequate
doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. Launch Date3.78518405E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
78.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3609112/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIFEDIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
148 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3609112/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIFEDIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3609112/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIFEDIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8% |
unknown |
NIFEDIPINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
90 mg single, oral Overdose |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: M Population Size: 1 Sources: |
Disc. AE: Tachycardia, Hyperglycemia... AEs leading to discontinuation/dose reduction: Tachycardia (grade 5, 1 patient) Sources: Hyperglycemia (grade 5, 1 patient) |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Co-administed with:: ethanol Sources: |
healthy, 34 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 34 years Sex: F Population Size: 1 Sources: |
Disc. AE: Hypotension, Acidosis... AEs leading to discontinuation/dose reduction: Hypotension (1 patient) Sources: Acidosis (1 patient) Hyperglycemia (1 patient) |
2400 mg single, oral Overdose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Co-administed with:: ethanol Sources: |
unknown, 37 years n = 1 Health Status: unknown Age Group: 37 years Sex: M Population Size: 1 Sources: |
Disc. AE: Intestinal infarction... AEs leading to discontinuation/dose reduction: Intestinal infarction (1 patient) Sources: |
300 mg single, oral Overdose |
unknown, 54 years n = 1 Health Status: unknown Condition: attempt to commit suicide Age Group: 54 years Sex: F Population Size: 1 Sources: |
Disc. AE: Reflex tachycardia... AEs leading to discontinuation/dose reduction: Reflex tachycardia (1 patient) Sources: |
600 mg single, oral Overdose |
unknown, 57 years n = 1 Health Status: unknown Age Group: 57 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hypotension, Tachycardia... AEs leading to discontinuation/dose reduction: Hypotension (1 patient) Sources: Tachycardia (1 patient) Flushing (1 patient) |
900 mg single, oral Overdose |
unhealthy, 59 years n = 1 Health Status: unhealthy Condition: with a history of angina, left bundle branch block, and depression Age Group: 59 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hypotension, Hyperglycemia... AEs leading to discontinuation/dose reduction: Hypotension (grade 4, 1 patient) Sources: Hyperglycemia (1 patient) |
180 mg 1 times / day steady, oral Highest studied dose Dose: 180 mg, 1 times / day Route: oral Route: steady Dose: 180 mg, 1 times / day Sources: |
unhealthy, adult n = 1000 Health Status: unhealthy Condition: hypertension and angina Age Group: adult Sex: unknown Population Size: 1000 Sources: |
DLT: Edema... Dose limiting toxicities: Edema (30%) Sources: |
30 mg 1 times / day steady, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 33.3 years n = 25 Health Status: unhealthy Condition: delivered at ≥32 weeks' gestation with persistent postpartum hypertension Age Group: mean 33.3 years Sex: F Population Size: 25 Sources: |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Sources: Vomiting (1 patient) Headache (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hyperglycemia | grade 5, 1 patient Disc. AE |
90 mg single, oral Overdose |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: M Population Size: 1 Sources: |
Tachycardia | grade 5, 1 patient Disc. AE |
90 mg single, oral Overdose |
healthy, 2 years n = 1 Health Status: healthy Age Group: 2 years Sex: M Population Size: 1 Sources: |
Acidosis | 1 patient Disc. AE |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Co-administed with:: ethanol Sources: |
healthy, 34 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 34 years Sex: F Population Size: 1 Sources: |
Hyperglycemia | 1 patient Disc. AE |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Co-administed with:: ethanol Sources: |
healthy, 34 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 34 years Sex: F Population Size: 1 Sources: |
Hypotension | 1 patient Disc. AE |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Co-administed with:: ethanol Sources: |
healthy, 34 years n = 1 Health Status: healthy Condition: suicide attempt Age Group: 34 years Sex: F Population Size: 1 Sources: |
Intestinal infarction | 1 patient Disc. AE |
2400 mg single, oral Overdose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Co-administed with:: ethanol Sources: |
unknown, 37 years n = 1 Health Status: unknown Age Group: 37 years Sex: M Population Size: 1 Sources: |
Reflex tachycardia | 1 patient Disc. AE |
300 mg single, oral Overdose |
unknown, 54 years n = 1 Health Status: unknown Condition: attempt to commit suicide Age Group: 54 years Sex: F Population Size: 1 Sources: |
Flushing | 1 patient Disc. AE |
600 mg single, oral Overdose |
unknown, 57 years n = 1 Health Status: unknown Age Group: 57 years Sex: M Population Size: 1 Sources: |
Hypotension | 1 patient Disc. AE |
600 mg single, oral Overdose |
unknown, 57 years n = 1 Health Status: unknown Age Group: 57 years Sex: M Population Size: 1 Sources: |
Tachycardia | 1 patient Disc. AE |
600 mg single, oral Overdose |
unknown, 57 years n = 1 Health Status: unknown Age Group: 57 years Sex: M Population Size: 1 Sources: |
Hyperglycemia | 1 patient Disc. AE |
900 mg single, oral Overdose |
unhealthy, 59 years n = 1 Health Status: unhealthy Condition: with a history of angina, left bundle branch block, and depression Age Group: 59 years Sex: M Population Size: 1 Sources: |
Hypotension | grade 4, 1 patient Disc. AE |
900 mg single, oral Overdose |
unhealthy, 59 years n = 1 Health Status: unhealthy Condition: with a history of angina, left bundle branch block, and depression Age Group: 59 years Sex: M Population Size: 1 Sources: |
Edema | 30% DLT |
180 mg 1 times / day steady, oral Highest studied dose Dose: 180 mg, 1 times / day Route: oral Route: steady Dose: 180 mg, 1 times / day Sources: |
unhealthy, adult n = 1000 Health Status: unhealthy Condition: hypertension and angina Age Group: adult Sex: unknown Population Size: 1000 Sources: |
Headache | 1 patient Disc. AE |
30 mg 1 times / day steady, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 33.3 years n = 25 Health Status: unhealthy Condition: delivered at ≥32 weeks' gestation with persistent postpartum hypertension Age Group: mean 33.3 years Sex: F Population Size: 25 Sources: |
Nausea | 1 patient Disc. AE |
30 mg 1 times / day steady, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 33.3 years n = 25 Health Status: unhealthy Condition: delivered at ≥32 weeks' gestation with persistent postpartum hypertension Age Group: mean 33.3 years Sex: F Population Size: 25 Sources: |
Vomiting | 1 patient Disc. AE |
30 mg 1 times / day steady, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 33.3 years n = 25 Health Status: unhealthy Condition: delivered at ≥32 weeks' gestation with persistent postpartum hypertension Age Group: mean 33.3 years Sex: F Population Size: 25 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
moderate | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
weak [IC50 186 uM] | ||||
weak [IC50 472 uM] | ||||
weak | ||||
weak | ||||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/11560876/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11560876/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11560876/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/14570758/ |
yes | |||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (co-administration study) Comment: [ADALAT® XL®PRODUCT MONOGRAPH]: Use of ADALAT XL with drugs that result in strong inhibition of CYP 3A4, such as ketoconazole, clarithromycin, ritonavir, may lead to increased plasma levels of nifedipine and associated serious adverse events. Such concomitant use should be avoided. |
|||
minor | ||||
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
[The effect of hypotensive nifedipine therapy on renal secretory function in hypertensive patients in the course of both compensated and non-compensated chronic renal failure]. | 1992 Dec 7-14 |
|
Lindane-induced convulsions in NMRI and OF1 mice: antagonism with (+)MK-801 and voltage-dependent calcium channel blockers. | 1992 Oct 16 |
|
Hypotension and coronary events on nifedipine: reassessing nifedipine safety. | 1998 Jun |
|
[The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension]. | 1998 Mar |
|
The influence of nifedipine on blood-brain barrier permeability during bicuculline-induced seizures. | 1999 Aug |
|
Reduced bcl-2 concentrations in hypertensive patients after lisinopril or nifedipine administration. | 1999 Jan |
|
Statins and peripheral neuropathy. | 1999 Jan |
|
Comparison between isosorbide dinitrate aerosol and nifedipine in the treatment of hypertensive emergencies. | 1999 Jul |
|
Ambulatory blood pressure profiles in essential hypertensives after treatment with a new once daily nifedipine formulation. | 1999 Mar |
|
[Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats]. | 1999 May |
|
Sublingual nifedipine in elderly patients: even a low dose induces myocardial ischaemia. | 1999 May-Jun |
|
A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. | 1999 Oct |
|
Acute hypotensive, natriuretic, and hormonal effects of nifedipine in salt-sensitive and salt-resistant black normotensive and hypertensive subjects. | 1999 Sep |
|
Effects of a slow-release nifedipine on 24-hour ambulatory blood pressure and ischemic changes on 24-hour ambulatory electrocardiogram in patients with severe coronary artery disease. | 2000 |
|
Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. | 2000 |
|
[Effects of calcium antagonists on atherosclerosis progression and intima media thickness]. | 2000 |
|
D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | 2000 Dec 15 |
|
Antiproteinuric effect of calcium antagonists on puromycin-induced experimental nephrosis. | 2000 Jan |
|
Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. | 2000 Jan 25 |
|
Losartan: a review of its use, with special focus on elderly patients. | 2000 Mar |
|
Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. | 2000 May |
|
Stroke precipitated by moderate blood pressure reduction. | 2000 Nov |
|
Keratinocyte growth factor is upregulated by the hyperplasia-inducing drug nifedipine. | 2000 Oct |
|
Adverse neurologic events associated with rebound hypertension after using short-acting nifedipine in childhood hypertension. | 2001 Dec |
|
Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. | 2001 Feb |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds. | 2002 |
|
Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. | 2002 Aug |
|
Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats. | 2002 Feb |
|
Evaluation of the safety of short-acting nifedipine in children with hypertension. | 2002 Jan |
|
[Drug induced anosmia with nifedipine]. | 2003 Aug 23 |
|
An in vitro bioassay for xenobiotics using the SXR-driven human CYP3A4/lacZ reporter gene. | 2003 May-Jun |
|
Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cells. | 2003 Nov |
|
Fatality from administration of labetalol and crushed extended-release nifedipine. | 2003 Oct |
|
Clinical review: the management of hypertensive crises. | 2003 Oct |
|
Proliferation of cultured human gingival fibroblasts caused by isradipine, a dihydropyridine-derivative calcium antagonist. | 2004 Jun 30 |
|
Adverse events associated with aggressive treatment of increased blood pressure. | 2004 May |
|
Xenoestrogens at picomolar to nanomolar concentrations trigger membrane estrogen receptor-alpha-mediated Ca2+ fluxes and prolactin release in GH3/B6 pituitary tumor cells. | 2005 Apr |
|
Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. | 2005 Apr |
|
Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. | 2005 Apr |
|
Examination of 209 drugs for inhibition of cytochrome P450 2C8. | 2005 Jan |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Nifedipine gastrointestinal therapeutic system--hypertension management to improve cardiovascular outcomes. | 2005 Sep |
|
Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices: correlation study with induction in vivo. | 2005 Sep-Oct |
Sample Use Guides
Therapy should be initiated with the 10 mg capsule. The starting dose is one 10 mg capsule, swallowed whole, 3 times/day. The usual effective dose range is 10–20 mg three times daily. Some patients, especially those with evidence of coronary artery spasm, respond only to higher doses, more frequent administration, or both. In such patients, doses of 20–30 mg three or four
times daily may be effective. Doses above 120 mg daily are rarely necessary. More than 180 mg per day is not recommended.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22923790
About 50% of the Ca(v) current was blocked by 10 uM of the L-type channel blocker nifedipine in human induced pluripotent stem cell-derived neurons.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:02:57 UTC 2021
by
admin
on
Fri Jun 25 21:02:57 UTC 2021
|
Record UNII |
I9ZF7L6G2L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC08GA01
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
FDA ORPHAN DRUG |
57991
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
NDF-RT |
N0000000069
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
WHO-ATC |
C08GA01
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
WHO-VATC |
QC08CA55
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
LIVERTOX |
684
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
NDF-RT |
N0000007556
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
WHO-ATC |
C08CA55
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
WHO-ATC |
C08CA05
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
WHO-VATC |
QC08CA05
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
22.2
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
||
|
NDF-RT |
N0000175421
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
NIFEDIPINE
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | Description. A yellow, crystalline powder.Solubility. Nifedipine is practically insoluble in water; freely soluble in acetone R; sparingly soluble in dehydrated ethanol R.Category. Cardiovascular drug; calcium-channel blocking agent.Storage. Nifedipine should be kept in a tightly closed container, protected from light.Additional information. CAUTION: Nifedipine decomposes on exposure to daylight, artificial light of certain wavelengths, andultraviolet light.Requirements: Nifedipine contains not less than 98.0% and not more than 102.0% of C17H18N2O6, calculated with reference to the driedsubstance.Note: Throughout the monograph perform the tests and the assay in the dark or under a suitable fluorescent light, using lowactinicglassware. | ||
|
DB01115
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
244-598-3
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
3222
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
21829-25-4
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
D009543
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
C29290
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
M7883
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | Merck Index | ||
|
I9ZF7L6G2L
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
SUB09253MIG
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
7775
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
21829-25-4
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
4485
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
7417
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | RxNorm | ||
|
2514
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
NIFEDIPINE
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
CHEMBL193
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
1922
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
Nifedipine
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | |||
|
1463508
Created by
admin on Fri Jun 25 21:02:57 UTC 2021 , Edited by admin on Fri Jun 25 21:02:57 UTC 2021
|
PRIMARY | USP-RS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR | |||
|
DEGRADENT -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
DEGRADENT -> PARENT |
LIGHT INDUCED DEGRADENT
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |